# TG Therapeutics (TGTX) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/TGTX
## Company Profile
- Ticker: TGTX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 49.5 USD
- Market cap: 5608982371.2 USD
- Last updated: 2026-08-12
## Business Overview
### B-Cell-Directed Therapies
TG Therapeutics develops and commercializes therapies targeting B cells in multiple sclerosis and other autoimmune diseases. Its portfolio combines an approved anti-CD20 antibody with alternative formulations and an allogeneic cell-therapy program.
### BRIUMVI
BRIUMVI, or ublituximab, is a glycoengineered CD20 monoclonal antibody approved for relapsing forms of multiple sclerosis. The antibody is designed for efficient B-cell depletion at a relatively low dose and is commercialized in the United States and through partners internationally.
### Formulation and Dosing Expansion
The company is conducting a pivotal program for subcutaneous ublituximab and the ENHANCE trial of a consolidated intravenous Day 1 and Day 15 dosing regimen. These studies aim to make administration more convenient while maintaining the established mechanism.
### Azer-Cel in Progressive MS
Azer-cel is an allogeneic CAR-T therapy being evaluated in progressive multiple sclerosis and other autoimmune diseases. The program tests whether deeper immune-cell resetting can benefit patients beyond conventional antibody-mediated B-cell depletion.
## Why The Stock Is Moving

As of Aug 12, 2026, TGTX closed down 0.80% at $49.50. No new same-company headline was identified in the current news window.

## Future Catalysts

- Topline ENHANCE pivotal data for consolidated intravenous BRIUMVI dosing expected in mid-2026.
- Preliminary Phase 1 azer-cel data in progressive multiple sclerosis expected in the second half of 2026.
- Pivotal subcutaneous BRIUMVI topline data expected around year-end 2026 or the first quarter of 2027.

## Recent News
- 2026-08-03 11:00 EST — [TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance](https://biopharmsignal.com/news/TGTX/tg-therapeutics-reports-second-quarter-2026-financial-results-and-raises-briumvi-ccdc59b0) — Source: TG Therapeutics
- 2026-07-29 11:30 EST — [TG Therapeutics to Host Conference Call on Second Quarter 2026 Financial Results and Business Update](https://biopharmsignal.com/news/TGTX/tg-therapeutics-to-host-conference-call-on-second-quarter-2026-financial-results-190cd0b2) — Source: TG Therapeutics
- 2026-07-06 11:30 EST — [TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia](https://biopharmsignal.com/news/TGTX/tg-therapeutics-announces-initiation-of-phase-2-trial-evaluating-briumvi-in-pati-4f9159d1) — Source: TG Therapeutics
- 2026-06-09 11:30 EST — [TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial](https://biopharmsignal.com/news/TGTX/tg-therapeutics-announces-positive-topline-phase-1-data-for-subcutaneous-briumvi-60f03f06) — Source: TG Therapeutics
- 2026-06-03 11:30 EST — [TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)](https://biopharmsignal.com/news/TGTX/tg-therapeutics-announces-positive-results-from-phase-1-trial-evaluating-subcutaneous-briumvir-ublituximab-xiiy) — Source: TG Therapeutics